

> BACTEREMIA


# BACTEREMIA & ENDOCARDITIS

BACTEREMIA

原因

• 1° infxn due to direct inoculation of the blood, frequently assoc with intravascular catheters. Catheter-related bloodstream infection = same org from peripheral cx _and_ cath tip cx _or_ cx drawn from catheter (_CID_ 2009;49:1).

• 2° infxn due to infection in another site (eg, UTI, lung, biliary tree, skin) spreading to blood

Microbiology

• Coag-neg staph 34%, _S. aureus_ 10%, enterococci 16%, _Candida_ 12%, GNRs 5%

• _Clostridium septicum_, _Bacteroides_, & _S. bovis_ a/w colon ca (_Gastro_ 2018;155:383)

• Bacteremia with encapsulated organisms (_S. pneumo, Neisseria, Haemophilus_, Group A strep) may indicate 1° immunodeficiency (_Clin Microbiol Infect_ 2017;8:576)

Risk factors for true bacteremia (_JAMA_ 2012;308:502)

• Fever, **shaking chills** and poor food consumption (_J Hosp Med_ 2017;12:510), SIRS (96% Se), IVDU, comorbidities, immunosupp, indwelling lines

• **Organism**

more likely pathogenic: _S. aureus_, β-hemolytic strep, enterococci, GNR, _S. pneumo, Neisseria_

less likely pathogenic: coag-neg staph (~10%), diphtheroids, _Propionibacterium_ (~0%)

• **Time to growth:** <24 h → higher risk, >72 h → lower risk (except for slow-growing organisms such as HACEK group)

• **Factors increasing likelihood of endocarditis:** high-grade bacteremia without source, persisting after line removal or drainage of focal source, in hosts at risk for endocarditis or with organisms known to cause IE; emboli

Diagnosis

• Obtain BCx prior to 抗生素 if possible, ≥2 sets (2 bottles in each set, each with 10 cc blood)

• If proven bacteremia, daily surveillance cxs until 48 hrs of ⊖ cxs. May not need for GNRs (_ClD_ 2017;65:1776).

• If _S. aureus_ or _S. lugdunensis_ obtain **TEE**. TTE for high-grade Strep bacteremia. No need for routine echos for GNR bacteremia.

治療

• Antibiotics based on Gram stain/culture results; tailor 抗生素 to sensitivities

empiric therapy for GPC: vanco to cover coag-neg staph and MRSA while awaiting sensi

• _S. aureus_ bacteremia: ID consult associated with lower mortality (_ClD_ 2015;60:1451).

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>Short-Term Central Venous Catheter-Related Bloodstream Infections</b> <span>(</span><span><i>CID</i></span> <span>2009;49:</span><span>1</span><span>)</span></p></td></tr><tr><td><p><b><i>S. aureus</i></b></p></td><td><p><b>Risk of endocarditis in bacteremia:</b> ~25% <span>(</span><span><i>JACC</i></span> <span>1</span><span>997;30:</span><span>1</span><span>072)</span></p><p>D/c CVC, TEE to 排除 endocarditis; if TEE ⊖ <i>and</i> not immunosupp. <i>and</i> no intravasc prosthesis, Rx × 2 wk from first ⊖ BCx. If no echo obtained, Rx × 4–6 wk.</p><p><b>Preferred 抗生素:</b> MSSA → nafcillin or cefazolin; MRSA → vancomycin</p></td></tr><tr><td><p><b>Coag-neg staphylococci</b></p></td><td><p>May consider keeping catheter. Catheter retention does not ↓ rate of bacteremia resolution, but a/w ↑ rate of recurrence <span>(</span><span><i>CID</i></span> <span>2009;49:</span><span>11</span><span>87)</span>.</p><p>If catheter left in place, Rx × 10–14 d and consider 抗生素 or ethanol lock</p><p>If catheter d/c, Rx × 5–7 d</p></td></tr><tr><td><p><b><i>Enterococcus</i></b></p></td><td><p><b>D/c catheter</b> &amp; Rx × 7–14 d</p></td></tr><tr><td><p><b>GNR</b></p></td><td><p>Rx × 7–14 d. 抗生素 based on sensitivities. <b>D/c catheter</b> if <i>Pseudomonas.</i></p></td></tr><tr><td><p><b>Fungi</b></p></td><td><p><b>D/c catheter</b> &amp; Rx × 14 d from first ⊖ BCx</p></td></tr></tbody></table>

• **Persistently** ⊕ **BCx:** d/c indwelling catheters, consider metastatic infxn, infected thrombosis or infected prosthetic material (joint, abscess, vascular graft, PPM, etc.)

BACTERIAL ENDOCARDITIS

定義

• Infection of endothelium of heart (including but not limited to the valves)

Predisposing conditions

• **Abnormal valve**

_High risk:_ prior endocarditis, prosthesis, cyanotic congenital heart (unrepaired), VADs, rheumatic heart disease, AoV disease (incl. bicuspid)

_Medium risk:_ MV disease (including MVP with MR or thickened leaflet), HCMP

• **Risk of bacteremia:** IVDU, indwelling venous catheters, poor dentition, hemodialysis, DM, prosthetic material in heart (eg, pacemaker, ICD, graft)

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><a id="page_6-13"></a><p><b>Modified Duke Criteria</b></p></td></tr><tr><td><p><b>Major</b></p></td><td><p><b>Minor</b></p></td></tr><tr><td><p><span>•</span> <b>BCx</b> with common endocarditis pathogen (grown in 2 separate cultures)</p><p><span>•</span> <i>Coxiella</i> serology ≥1:800</p><p><span>•</span> <b>Endocardial involvement</b>, with either: <b>echocardiogram</b> with vegetation, abscess, or prosthetic dehiscence<br><b>new valvular regurgitation</b></p></td><td><p><span>•</span> Predisposing condition (see above)</p><p><span>•</span> Fever</p><p><span>•</span> <b>Vascular phenomena:</b> septic arterial or pulmonary emboli, mycotic aneurysms, ICH, Janeway lesions</p><p><span>•</span> <b>Immune phenomena:</b> ⊕ RF, GN, Osler’s nodes, Roth spots</p><p><span>•</span> ⊕ <b>BCx</b> not meeting major criteria</p></td></tr><tr><td colspan="2"><p>Definitive (ie, highly probable): 2 major <i>or</i> 1 major + 3 minor <i>or</i> 5 minor criteria</p><p>Possible: 1 major + 1 minor <i>or</i> 3 minor criteria</p></td></tr></tbody></table>

Se ~90%, Sp >95%, NPV ≥92% (_CID_ 2000;30:633). \*Serologic or molecular tests for other known agents of Cx ⊝ endocarditis (see below) not yet included as major criterion, but may help dx.

![](https://i.imgur.com/OKaKrt1.jpg)

a↑ risk with DM, indwelling lines, immunosupp. bCx ⊖ = abiotrophic strep, HACEK (_Haemophilus para-influenzae_ & _aphrophilus, Actinobacillus, Cardiobacterium, Eikenella_ and _Kingella_), _T. whipplei_, _Bartonella, Coxiella, Chlamydia, Legionella, Brucella_ (_JAMA_ 2007;297:1354; _Annals_ 2007;147:829; _J Clin Microbiol_ 2012;50:216)

臨床表現 (_Lancet_ 2016;387:882)

• **Persistent bacteremia: fever** (80–90%), rigors, night sweats, anorexia, wt loss, fatigue

• **Valvular or perivalvular infection:** CHF, conduction abnormalities

• **Septic emboli:** stroke, PE (if right-sided), mycotic aneurysm, MI (coronary artery embolism), CNS, kidneys, spleen, joints

• **Immune complex phenomena:** arthritis, glomerulonephritis, ⊕ RF, ↑ ESR

• _Subacute_ (less-virulent pathogens) can 表現為 fatigue, nonspecific sx in 病人 without risk factors

Physical exam

• HEENT: **Roth spots** (retinal hemorrhage + pale center), **petechiae** (conjunctivae, palate)

• Cardiac: **murmur** (85%), **new valve regurgitation** (40–85%) ± thrill (fenestrated valve or ruptured chordae), muffled sounds (PV). _Frequent exams_ for Δ murmurs, signs and symptoms CHF.

• Extremities

### Janeway lesions (septic emboli → nontender, hemorrhagic macules on palms or soles)

### Osler’s nodes (immune complexes → tender nodules on pads of digits)

_proximal_ nail bed splinter hemorrhages (8–15%); petechiae (33%); clubbing; arthritis

• Δ MS or focal deficits, vertebral tenderness

• Devices: erythema, tenderness or drainage at catheter site, PM/ICD pocket tenderness

Diagnosis (_CID_ 2010;51:131; _EHJ_ 2015;36:3075; _Circ_ 2015;132:1435)

• **Blood cultures** (_before 抗生素_): 3 sets (aerobic & anaerobic bottles) from different sites, ideally spaced ≥1 h apart. ✔ BCx (at least 2 sets) after appropriate 抗生素 have been initiated to document clearance; repeat q24–48h until ⊖.

• **ECG** (on admission and at regular intervals) to assess for new conduction abnormalities

• **Echocardiogram:** _TTE in all_. Obtain **TEE** if (i) TTE nondx (ii) TTE ⊖ but high suspicion, (iii) high-risk (prosthetic valve, prior IE, congenital heart dis.), or (iv) suspect progressive or invasive infxn (eg, persistent bacteremia or fever, new conduction 異常, etc.)

![](https://i.imgur.com/rrHWldl.jpg)

(_Mayo Clin Proc_ 2014;89:799; _Circ_ 2015;132:1435; _Eur Radiol_ 2015; 25:2125; _J Am Soc Echo_ 2016;29:315)

• Addition of PET/CT or MRI helpful to assess for periannular complications in PVE

• **Brain/spine imaging** necessary in those who develop severe HA, neurologic deficits, meningeal signs. Consider in any patient with left-sided endocarditis (_Circ_ 2015;132:1435).

• **Cx** ⊖ **endocarditis:** may be due to 抗生素 prior to BCx. PCR, bacterial 16S ribosomal RNA, serol. may be helpful. Detailed hx: animal exposure, travel, unpast. dairy, etc. ID eval.

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><a id="page_6-14"></a><p><b>治療</b> <span>(<i>Circ</i> 2015;132:1435)</span></p></td></tr><tr><td><p><b>Organism</b></p></td><td><p><b>Specific Considerations</b></p></td></tr><tr><td><p><b>Empiric</b></p></td><td><p>NVE or PVE &gt;12 mo post-op: Vanc + CTX PVE &lt;12 mo post op: Vanc + CTX + gent</p></td></tr><tr><td><p><i>Strep</i></p></td><td><p><i>S. bovis</i> a/w colon cancer. Penicillin, Amp, CTX</p></td></tr><tr><td><p><i>Staph</i></p></td><td><p><span>•</span> MRSA: vanc or dapto; MSSA: nafcillin or cefazolin</p><p><span>•</span> Obtain ID consult</p><p><span>•</span> Vanc inferior to beta lactam for long-term MSSA Rx</p><p><span>•</span> For PCN allergy with MSSA, undergo desensitization</p><p><span>•</span> Do not use cefazolin for CNS involvement b/c poor penetration</p><p><span>•</span> Rif (+ AG × 2 wk to prevent resistance) should be added in PVE</p><p><span>•</span> <i>S. lugdunensis</i> is <i>virulent</i> and should be treated like <i>S. aureus</i></p></td></tr><tr><td><p><i>Enterococcus</i></p></td><td><p>Ampicillin + [CTX or gent]; VRE needs linezolid or dapto</p></td></tr><tr><td><p>GNRs</p></td><td><p>HACEK: CTX. <i>Pseudomonas</i>: 2 anti-Pseudomonal agents [eg, B-lactam + (AG or quinolone)]; consult ID.</p></td></tr><tr><td><p>Fungi</p></td><td><p>Liposomal ampho or micafungin. Risk factors: TPN, lines, pacemaker/ICD, prothesis, IVDU. <i>Ophtho consult for candidemia.</i></p></td></tr><tr><td colspan="2"><p><b>Early surgical consult for any prosthetic valve infection regardless of organism</b></p></td></tr></tbody></table>

• De-escalate 抗生素 to organism-directed therapy once sensitivities return

• Repeat BCx q24–48h until Pt defervesces and BCx ⊖

• Anticoag. controversial; d/c for ≥2 wk if PVE and CNS embolic event. Can continue antiplatelet Rx if no CNS event in all comers, but no proven benefit to adding.

• Monitor for complications of endocarditis (CHF, conduction block, new emboli, etc., which can occur even on 抗生素) and of 抗生素 Rx (interstitial nephritis, ARF, neutropenia, etc.)

• Duration of Rx: usually **4–6 wk**

After ≥10d IV 抗生素, if doing well, and depending on organism, Pt, & 抗生素 choices, may consider Δ’ing to PO in consultation with ID (_NEJM_ 2019;380:415)

Uncomplicated right-sided NVE or PCN-S strep spp → 2 wk may be comparable

Indications for surgery (_EHJ_ 2015;36:3075)

• **Severe valvular dysfunction** → **refractory CHF:** _emergent_ if refractory cardiogenic shock (ie, despite ICU-level Rx); _urgent_ (w/in days) if persistent refractory heart failure; _elective_ (w/in wks) if asx severe AI or MR. Consult cardiac surgery early.

• **Uncontrolled infxn** (typically urgent surgery within days): periannular abscess (10–40% NVE, 60–100% PVE), heart block, fistula, worsening conduction, PVE with dehiscence, ↑ veg. size or persistent sepsis (eg, ⊕ BCx after ~1 wk of appropriate IV 抗生素 & no drainable metastatic focus or other identifiable cause; complicated if due to septic emboli to lung)

• **Organism:** consider surgery for _S. aureus_, fungal or multiRx-resistant organisms

• **Prosthetic valve:** dysfunction or dehiscence

• **Systemic embolism** (20–50%): risk 4.8/1000 Pt days in 1st wk, 1.7/1000 thereafter. Urgent surgery if L-sided with >10 mm veg & severe AI/MR (_NEJM_ 2012;366:2466) or if recurrent emboli, embolism & >10 mm veg, or >15 mm veg despite approp. 抗生素.

• **Cerebral emboli** no longer considered contraindic to surgery unless severe stroke or hemorrhage (then ideally wait 1 mo) (_Stroke_ 2006;37:2094)

Prognosis

• NVE: non-IVDU _S. aureus_ → 30–45% mortality; IVDU _S. aureus_ (often right-sided) → 10–15% mortality; SBE → 10–15% mortality

• PVE → 23% mortality

<table><colgroup><col> <col></colgroup><tbody><tr><td colspan="2"><p><b>Endocarditis Prophylaxis</b> <span>(<i>Circ</i> 2007;116:1736)</span></p></td></tr><tr><td><p><b>Cardiac conditions</b><a id="st10"></a><a href="text/part0011_split_006.html#sst10">*</a></p></td><td><p><b>Prosthetic valve; previous NVE; congenital heart disease</b> (CHD) including unrepaired or incompletely repaired cyanotic CHD (palliative shunts or conduits), 1<sup>st</sup> 6 mo after completely repaired CHD using prosthetic material; <b>cardiac transplant recipients with valvulopathy</b></p><p>(Prophylaxis no longer rec. in acquired valvular dysfxn, bicuspid AoV, MVP with leaflet thickening or regurgitation, HCMP)</p></td></tr><tr><td><p><b>Procedures</b><a href="text/part0011_split_006.html#sst10">*</a></p></td><td><p><b>Dental:</b> manipulation of gingival tissue or periapical region of teeth or perf oral mucosa (eg, extraction, periodontal, implant, root canal, cleaning)</p><p><b>Respiratory:</b> incision or biopsy of respiratory mucosa</p><p>(no prophylaxis for GI or GU procedures)</p></td></tr><tr><td><p><b>Regimens</b></p></td><td><p>Oral: <b>amoxicillin 2 g 30–60 min before</b></p><p>Unable to take PO: amp 2 g IM/IV or cefazolin or Cftx 1 g IM/IV</p><p>PCN-allergic: clinda 600 mg PO/IM/IV</p></td></tr></tbody></table>

[\*](text/part0011_split_006.html#st10)Pts should meet both indications (high-risk condition & high-risk procedure) to qualify for Ppx
